Hormonal
Antiobesity medications (AOMs), particularly GLP-1/GIP receptor agonists like semaglutide and tirzepatide, are effective adjuncts to lifestyle modifications for achieving clinically significant weight loss (>5-10% total body weight) in patients with BMI >30 (or >27 with comorbidities).
If you have a BMI over 30 (or 27 with health issues), lifestyle changes alone may not be enough for lasting results. Talk to your doctor about GLP-1/GIP medications like semaglutide or tirzepatide. These are weekly injections that help with appetite and satiety. They work best when combined with diet and exercise changes, and your doctor should monitor your nutrition to prevent deficiencies.
In many patients, antiobesity medications (AOMs) play a role in sustainable intervention and are appropriate in patients with a BMI >30 or >27 with weight-related comorbidities... The newest and currently most efficacious AOMs are semaglutide and tirzepatide, which are long-acting GLP-1/GIP receptor agonists... Older classes of medications result in an average of 5%–10% TBW loss, and newer classes result in an average of 10%–20% TBW.
Why this rating
Based on a narrative review citing multiple clinical trials and FDA approvals, though not a primary RCT itself.
Source
Key messages on obesity care from the 2023 ASPEN Physician Preconference Course: A narrative review
Givi Basishvili et al. · Journal of Parenteral and Enteral Nutrition · 2024
DOI 10.1002/jpen.2632
More from this paper
- Metabolic and bariatric surgery (MBS) is an effective means of durable weight loss, with sleeve gastrectomy being the most performed procedure, offering significant long-term weight loss and diabetes remission.Strong
- Sarcopenic obesity, characterized by the combination of obesity and loss of lean muscle mass, is a significant nutrition risk that requires specific monitoring and interventions like enhanced protein intake and weight-bearing exercise.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →